Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEWFLAME: Nivolumab + abemaciclib + endocrine therapy in HR-positive HER2-negative metastatic breast cancer
jRCT2080224706Phase 2Terminated
- Sponsor
- Toshimi Takano
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab, abemaciclib, letrozole and fulvestrant in breast cancer (2 cohorts), sponsored by Toshimi Takano. Started Jun 2019; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080224706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224706.